

frequency of ophthalmologist visits, probability of surgery and total costs. The user can specify country-specific treatment strategies, therapy discontinuation, surgical rates, practice patterns and costs. **RESULTS:** The key challenges included: selection of a disease outcome that was relevant to current clinical practice; choice of time horizon; incorporation of therapy discontinuation; reflection of diversity in treatment options; and consideration of variability in patient response. **CONCLUSIONS:** Modeling the clinical and economic impacts of glaucoma treatment involve challenges shared with other chronic diseases where the definition of treatment success is patient-specific. The model offers insights into accommodating patient-specific variability through the use of persistence distributions from actual clinical practice. The model provides a clinically relevant tool for decision-makers and clinicians to assess management strategies for glaucoma.

**PMD29****A MULTI-OUTCOME DECISION MODEL FOR PARKINSON'S DISEASE**

Siebert U<sup>1</sup>, Bornschein B<sup>2</sup>, Sroczynski G<sup>1</sup>, Spottke A<sup>3</sup>, Dodel R<sup>3</sup>

<sup>1</sup>Harvard University, Boston, MA, USA; <sup>2</sup>University of Munich, Munich, Germany; <sup>3</sup>University of Bonn, Bonn, Germany

**OBJECTIVE:** To develop a generic decision-analytic model for the evaluation of long-term clinical and economic consequences of interventions in patients with Parkinson's disease (PD) which can be applied to different research questions, interventions, and outcomes, and is based on (untreated) biological progression. **METHODS:** We developed a Markov model, in which a hypothetical cohort of patients moves through health states reflecting patient characteristics that are observed under treatment (Hoehn and Yahr "on" state [HYon]) and would be observed in the absence of treatment (Hoehn and Yahr "off" state [HYoff]). We used HYoff I-V s as Markov states, because those reflect underlying biologic progression of PD. Interventions: diagnostic or treatment strategies in PD patients such as Levodopa, dopamine agonists, or other anti-parkinsonian drugs as well as surgical therapies such as deep brain stimulation. Data: Transition probabilities for HYoff states were derived from the literature. The distribution of HYon was modeled conditional on HYoff using studies that report both characteristic. Complications were modeled conditional on HYon using data from a registry established by the "Competence Network Parkinson Disease". Utilities, and costs were modeled conditional on HYon and presence of complication. Mortality is a function of age- and gender-specific background mortality and PD-specific mortality Time horizon: lifetime with annual cycle length. **RESULTS:** Remaining (quality-adjusted) life expectancy, direct costs, and incremental cost-effectiveness ratios. Further outcomes comprise clinical events or complications such as motor complications,

dementia, depression, and hallucinations. In addition, complication-free survival, time in HYoff and HYon states, and UPDRS scores were modeled as additional outcomes. Perspective: societal and third party payer. Sensitivity analysis: 1-way and multiway. An interactive interface allows to model different settings or countries. **CONCLUSIONS:** In contrast to formerly published models, this generic PD model has the ability to consider multiple interventions and outcomes and to switch between outcomes depending on which outcomes are reported in a clinical trial.

**PMD30****MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA**

Höer A<sup>1</sup>, Gothe H<sup>1</sup>, von Zahn J<sup>1</sup>, Glaeske G<sup>2</sup>, Häussler B<sup>1</sup>

<sup>1</sup>IGES Institut für Gesundheits- und Sozialforschung, Berlin, Germany; <sup>2</sup>Universität Bremen, Bremen, Germany

**OBJECTIVES:** The most wide-spread acid-related disorders are peptic ulcer disease (PUD) and gastroesophageal reflux (GERD). The literature indicates that during past years PUD had been diagnosed less frequently, whereas GERD had been diagnosed more often. Our study aimed at modelling the prevalence of PUD and GERD using claims data of a major sickness fund. The second aim was to quantify the drug expenditures for acid-related disorders and to analyse the outcomes of eradication therapy under non-interventional routine treatment conditions. **METHODS:** On the basis of prescription records from 2000 and 2001, insured persons were classified as GERD or PUD patients according to typical prescription patterns, to the diagnoses of sick leave periods and hospitalisations. According to this classification, the prevalence of acid-related disorders was modelled. Outcomes were analysed by comparing hospitalisations, sick leave periods and costs in groups with and without eradication therapy. **RESULTS:** From a total of 1,408,902 insured persons 134,759 had at least one antacid prescription. With regard to the defined prescription patterns we estimated a 2-year treatment prevalence of 3.93% and 3.77% for PUD and GERD, respectively. Within the 2-year period, drug expenditures for the treatment of acid-related disorders added up to €5.9 and €8.1 million, respectively. For 5,926 out of 41,301 people assumed to suffer from PUD, an eradication therapy could be detected. In groups without eradication therapy the risk for hospitalisation or sick leave periods was twice as high as in groups with eradication therapy. Hospitalisation costs were considerably higher, too. **CONCLUSIONS:** Although eradication therapy was found to reduce the risk for hospitalisation, sick leave periods and costs, this therapeutic approach was practised only for a minor proportion of patients suffering from PUD. Our findings suggest that there is still room for diagnostic and therapeutic improvement in the management of acid-related disorders.